m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05465
 [1]
m6A modification hsa-miR-221-3p hsa-miR-221-3p METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-221-3p HIPK2  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target hsa-miR-221-3p
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-221-3p microRNA View Details
Regulated Target Homeodomain-interacting protein kinase 2 (HIPK2) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating hsa-miR-221-3p maturation in a m6A-dependent manner. METTL3 knockdown was shown to reduce the expression of miR-221-3p by reducing pri-miR-221-3p m6A mRNA methylation, reducing the expression of MDR1 and BCRP, and inducing apoptosis. Identified the METTL3/miR-221-3p/Homeodomain-interacting protein kinase 2 (HIPK2)/Che-1 axis as a novel signaling event that will be responsible for resistance of BC cells to ADR.
Responsed Disease Melanoma ICD-11: 2C30
 Disease Info 
Responsed Drug RSL3
 Drug Info 
In-vitro Model
 501-mel Melanoma Homo sapiens CVCL_4633
SK-MEL-2 Melanoma Homo sapiens CVCL_0069
SK-MEL-28 Cutaneous melanoma Homo sapiens CVCL_0526
SK-MEL-147 Melanoma Homo sapiens CVCL_3876
A-375 Amelanotic melanoma Homo sapiens CVCL_0132
SK-MEL-173 Melanoma Homo sapiens CVCL_6090
SK-MEL-239 Melanoma Homo sapiens CVCL_6122
451Lu Cutaneous melanoma Homo sapiens CVCL_6357
WM278 Cutaneous melanoma Homo sapiens CVCL_6473
WM1361A Cutaneous melanoma Homo sapiens CVCL_6788
WM793 Melanoma Homo sapiens CVCL_8787
WM35 Melanoma Homo sapiens CVCL_0580
WM902B Melanoma Homo sapiens CVCL_6807
WM115 Melanoma Homo sapiens CVCL_0040
WM266-4 Melanoma Homo sapiens CVCL_2765
WM1552C Cutaneous melanoma Homo sapiens CVCL_6472
In-vivo Model 4-6 weeks old NOD/Shi-scid/IL-2Rgamma null (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)) mice (female).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Homeodomain-interacting protein kinase 2 (HIPK2) 1 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PMID24900749C1a Investigative [2]
Synonyms
GTPL8128; BDBM50437434
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 40 nM
External Link
CID: 72163809
TTD: D04TPA
2C30: Melanoma 253 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Toripalimab Approved in China [3]
External Link
TTD: D92OCI
 Compound Name Atezolizumab Approved [4]
External Link
TTD: D0YM2K
 Compound Name Vemurafenib Approved [5]
Synonyms
PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)
    Click to Show/Hide
External Link
CID: 42611257
TTD: D0Y9EW
DrugBank: DB08881
 Compound Name Dacarbazine Approved [6]
Synonyms
Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
    Click to Show/Hide
External Link
CID: 135398738
TTD: D0Y7ZU
DrugBank: DB00851
 Compound Name Bavencio Approved [4]
External Link
TTD: D0W8HN
 Compound Name Teplizumab Phase 3 [7]
External Link
TTD: D0VH4V
 Compound Name LGX818 Approved [8]
Synonyms
Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib)
    Click to Show/Hide
External Link
CID: 50922675
TTD: D0TK7R
DrugBank: DB11718
 Compound Name Tebentafusp Approved [9]
External Link
TTD: D0S0BJ
 Compound Name Lenvatinib Approved [10]
Synonyms
E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
    Click to Show/Hide
External Link
CID: 9823820
TTD: D0R0FO
DrugBank: DB09078
 Compound Name Interferon Alfa-2b Approved [11]
Synonyms
Intron A; Viraferon
    Click to Show/Hide
External Link
CID: 71306834
TTD: D0P0WV
 Compound Name Osimertinib Approved [12]
Synonyms
Tagrisso
    Click to Show/Hide
External Link
CID: 71496458
TTD: D0O8GK
DrugBank: DB09330
 Compound Name Tremetinib Approved [13]
External Link
TTD: D0N7XI
 Compound Name Durvalumab Approved [14]
External Link
TTD: D0LS9E
 Compound Name Cemiplimab Approved [8]
Synonyms
REGN2810; REGN-2810; REGN 2810
    Click to Show/Hide
External Link
TTD: D0KG4Q
 Compound Name Avelumab Approved [14]
External Link
TTD: D0K7SX
 Compound Name Omaveloxolone Approved [4]
Synonyms
RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563
    Click to Show/Hide
External Link
CID: 71811910
TTD: D0JB3H
DrugBank: DB12513
 Compound Name Isoproterenol Approved [15]
Synonyms
Isoprenaline; Isoprenalin; Norisodrine; Novodrin; Isopropydrin; Isopropylarterenol; Respifral; Assiprenol; Asiprenol; Bellasthman; Asmalar; Aludrine; Aludrin; N-Isopropylnoradrenaline; Bronkephrine; Neodrenal; Lomupren; Isonorene; Isopropyladrenaline; 7683-59-2; N-Isopropylnorepinephrine; Isopropylnorepinephrine; neo-Epinine; Isadrine; Saventrine; Isorenin; Isonorin; Proternol; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Vapo-N-iso; Aerolone; Aleudrine; Dihydroxyphenylethanolisopropylamine; Euspiran; ISOPROP; Isadrin; Isoproterenolum; Isuprel; Isupren; Izadrin; Epinephrine isopropyl homolog; Isoprenaline hydrochloride; Isoproterenol Chloride; Isoproterenol [JAN]; Isuprel Mistometer; WIN 5162; D-Isoprenaline; D-Isopropylarterenol; D-Isoproterenol; DL-Isopropylnorepinephrine; Dl-Ipr; Dl-Isopropylnoradrenaline; Isoprenalina [INN-Spanish]; Isoprenaline (INN); Isoprenalinum [INN-Latin]; Isuprel (TN); L-Isopropylnoradrenaline; L-Isoproterenol; Medihaler-ISO; Vapo-Iso; Alpha-(Isopropylaminomethyl)protocatechuyl alcohol; Alpha-(Isopropylaminomoethyl)protocatechuyl alcohol; D-N-Isopropylnorepinephrine; Dl-N-Isopropylnoradrenaline; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL(+-)-Isoproterenol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (+)-Isoprenaline; (+)-Isoproterenol; (+-)-Isoprenaline; (-)-Isoproterenol hydrochloride; (S)-(+)-Isoproterenol; (S)-Isoprenaline; (S)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-(9CI); 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-(9CI); 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,4-Dihydroxy-alpha-(isopropylaminomethyl)-benzyl alcohol; 3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; AS1409
    Click to Show/Hide
External Link
CID: 3779
TTD: D0I8FI
DrugBank: DB01064
 Compound Name Thymalfasin Phase 2 [16]
Synonyms
Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1
    Click to Show/Hide
External Link
CID: 16130571
TTD: D0I5KX
 Compound Name Melacine Approved [11]
Synonyms
Melanoma vaccine (Detox-B), Corixa; Melanoma theraccine (Detox-B), Biomira/Ribi; Melanoma vaccine (Detox-B), Biomira/Ribi; Melanomavaccine (Detox-B), Corixa/Schering-Plough
    Click to Show/Hide
External Link
TTD: D0HV7K
 Compound Name Ingenol mebutate Phase 3 [17]
Synonyms
Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[ ]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A
    Click to Show/Hide
External Link
CID: 6918670
TTD: D0E9KA
DrugBank: DB05013
 Compound Name ARRY-162 Approved [8]
Synonyms
606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); NVP-ME
    Click to Show/Hide
External Link
CID: 10288191
TTD: D0C4LF
DrugBank: DB11967
 Compound Name Relatlimab Approved [18]
External Link
TTD: D0A3WJ
 Compound Name Tc-99m tilmanocept Approved [19]
Synonyms
Lymphoseek (TN)
    Click to Show/Hide
External Link
TTD: D09XVS
 Compound Name Palladium Pd 103 Approved [11]
Synonyms
Palladium-103
    Click to Show/Hide
External Link
CID: 9793711
TTD: D09XOR
DrugBank: DB15016
 Compound Name Pembrolizumab Approved [4]
External Link
TTD: D08ANZ
 Compound Name HybriCell Approved [11]
Synonyms
Dendritic cell-tumor cell hybrid vaccine (melanoma, RCC), Genoa
    Click to Show/Hide
External Link
TTD: D07YUH
 Compound Name MK-3475 Approved [20]
External Link
TTD: D07DMY
 Compound Name Ipilimumab Approved [21]
Synonyms
BMS-734016; MDX-010; MDX-101; Yervoy (TN)
    Click to Show/Hide
External Link
TTD: D07BVI
 Compound Name Trametinib + dabrafenib Approved [22]
External Link
CID: 11707110
TTD: D06AGH
DrugBank: DB08911
 Compound Name Dabrafenib Approved [13]
Synonyms
1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436
    Click to Show/Hide
External Link
CID: 44462760
TTD: D05ROI
DrugBank: DB08912
 Compound Name 99mTc-depreotide Approved [11]
Synonyms
NeoSpect; NeoTect; P829 Techtide; Technetium-99m P829; Technetium-99m depreotide; 99mTc-P829
    Click to Show/Hide
External Link
TTD: D05HWX
 Compound Name Talimogene Laherparepvec Approved [11]
Synonyms
IMLYGIC
    Click to Show/Hide
External Link
TTD: D05BXY
 Compound Name Treosulfan Approved [23]
Synonyms
Tresulfan; Dimesyl-meso-erythritol; Erythritol, 1,4-dimethanesulfonate; Erythritol, dimesyl-, meso-; Dihydroxymyleran; Dihydroxybusulfan; 1,4-Di(methanesulfonate)erythritol; NSC 94160; L-Threityl dimesylate; Erythritol, 1,4-bis(methanesulfonate); Threitol-1,4-bismethanesulfonate, meso-; CB 40069; 1,4-Bis(methanesulfonyloxy)-2,3-butanediol; 1,4-Bis(methylsulfonyloxy)threitol; Threitol 1,4-bis(methanesulfonate); ERYTHRITOL, 1,4-DIMETHANESULFONATE, (meso)-; NCGC00181153-01; L-Threitol 1,4-dimethanesulfonate
    Click to Show/Hide
External Link
CID: 9882105
TTD: D04YPN
DrugBank: DB11678
 Compound Name Trametinib Approved [24]
Synonyms
GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN
    Click to Show/Hide
External Link
CID: 11707110
TTD: D04XVN
DrugBank: DB08911
 Compound Name Nivolumab Approved [25]
External Link
TTD: D00GOV
 Compound Name HBI-8000 Phase 1/2 [14]
Synonyms
CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide
    Click to Show/Hide
External Link
CID: 12136798
TTD: D00SQN
DrugBank: DB06334
 Compound Name OncoVAX Preregistration [26]
Synonyms
Cancer vaccine, Vaccinogen; OncoVAX, Vaccinogen; Autologous vaccine (colon cancer), Vaccinogen; OncoVAX-CL, Intracel; Vaccine(colon cancer), Intracel; Vaccine (colon cancer), Vaccinogen
    Click to Show/Hide
External Link
TTD: D0UR1Z
 Compound Name MPL-containing Pollinex allergy desensitization vaccine Preregistration [27]
Synonyms
HDM SC vaccine, Allergy Therapeutics; House dust mite SC vaccine, Allergy Therapeutics; Pollinex Quattro (house dust mite allergy vaccine); Quattro MPL (house dust mite allergy vaccine); MPL-containing Pollinex allergy desensitization vaccine (house dust mites); MPL-containing Pollinex allergy desensitization vaccine (house dust mites), Allergy Therapeutics
    Click to Show/Hide
External Link
TTD: D01FWR
 Compound Name Tilsotolimod Phase 3 [28]
Synonyms
IMO-2125
    Click to Show/Hide
External Link
TTD: D6YD0X
 Compound Name NKTR-214 Phase 3 [29]
Synonyms
bempegaldesleukin
    Click to Show/Hide
External Link
TTD: D5ISZ1
 Compound Name Nemvaleukin alfa Phase 3 [30]
External Link
TTD: D1I0LQ
 Compound Name Melanoma vaccine, University of Virginia Phase 3 [17]
Synonyms
Vaccine (melanoma); Melanoma-specific antigens, Argonex; Peptide vaccine/autologous dendritic cells, Argonex; Vaccine (melanoma), Argonex; Vaccine (melanoma), University of Virginia
    Click to Show/Hide
External Link
TTD: D0Z3ES
 Compound Name Velimogene aliplasmid Phase 3 [31]
Synonyms
Allovectin (TN)
    Click to Show/Hide
External Link
TTD: D0Y9YN
 Compound Name MPDL-3280A Phase 3 [32]
External Link
TTD: D0Y5IH
 Compound Name Seviprotimut-L Phase 3 [33]
External Link
TTD: D0V0AF
 Compound Name Melanoma vaccine Phase 3 [34]
Synonyms
NA17.A2 peptides, Institut Curie; Vaccine (melanoma), Institut Curie; Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100); Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100), Institut Curie
    Click to Show/Hide
External Link
TTD: D0U9MJ
 Compound Name Selumetinib Phase 3 [35]
Synonyms
AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U
    Click to Show/Hide
External Link
CID: 10127622
TTD: D0T5DP
DrugBank: DB11689
 Compound Name ABT-888 Phase 3 [10]
Synonyms
Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride
    Click to Show/Hide
External Link
CID: 45480520
TTD: D0Q7UD
 Compound Name Multi-epitope peptide melanoma vaccine Phase 3 [34]
Synonyms
Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b
    Click to Show/Hide
External Link
TTD: D0P5TG
 Compound Name AMD-070 Phase 3 [14]
Synonyms
AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate
    Click to Show/Hide
External Link
CID: 11256587
TTD: D0O2XQ
DrugBank: DB05501
 Compound Name SNDX-275 Phase 3 [14]
Synonyms
Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate
    Click to Show/Hide
External Link
CID: 4261
TTD: D0M8FD
DrugBank: DB11841
 Compound Name Canvaxin Phase 3 [36]
Synonyms
Cancer vaccine, CancerVax; Melanoma vaccine, John Wayne Cancer Institute; Polyvalent melanoma cancer vaccine (PMCV)
    Click to Show/Hide
External Link
TTD: D0M4TF
 Compound Name PV-10 Phase 3 [37]
Synonyms
632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium
    Click to Show/Hide
External Link
CID: 69438
TTD: D0L2VT
 Compound Name Pegargiminase Phase 2 [10]
Synonyms
ADI-PEG-20
    Click to Show/Hide
External Link
TTD: D0KB0Y
 Compound Name RG7421+RG7204 Phase 3 [38]
Synonyms
Cobimetinib+vemurafenib; Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)
    Click to Show/Hide
External Link
TTD: D0I5EU
 Compound Name INCB24360 Phase 2 [14]
Synonyms
Epacadostat
    Click to Show/Hide
External Link
CID: 135564890
TTD: D0G7MV
DrugBank: DB11717
 Compound Name IMO-2125 Phase 3 [14]
External Link
TTD: D0FM5M
 Compound Name Cotellic Phase 3 [4]
Synonyms
Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate
    Click to Show/Hide
External Link
CID: 16222096
TTD: D0FJ9I
DrugBank: DB05239
 Compound Name Tesetaxel Phase 2 [39]
Synonyms
DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE
    Click to Show/Hide
External Link
CID: 6918574
TTD: D0F9VH
DrugBank: DB12019
 Compound Name BMS-986205 Phase 3 [14]
Synonyms
KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-
    Click to Show/Hide
External Link
CID: 121328278
TTD: D0DP5I
DrugBank: DB14986
 Compound Name Daromun Phase 3 [14]
Synonyms
darleukin + fibromun
    Click to Show/Hide
External Link
TTD: D0CR9L
 Compound Name SD-101 Phase 1/2 [14]
Synonyms
HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo
    Click to Show/Hide
External Link
TTD: D08RJM
 Compound Name Javelin Phase 3 [40]
Synonyms
MJV-101
    Click to Show/Hide
External Link
CID: 104768
TTD: D08PCH
 Compound Name Spartalizumab Phase 3 [41]
External Link
TTD: D08JLH
 Compound Name Melapuldencel-T Phase 3 [42]
External Link
TTD: D06ZJD
 Compound Name Oblimersen Phase 3 [43]
External Link
CID: 118984457
TTD: D05RJP
 Compound Name PDR001 Phase 3 [44]
External Link
TTD: D05BAJ
 Compound Name GMK Phase 3 [45]
Synonyms
(3-Deoxy-3-(3-Methoxy-Benzamido)-B-D-Galactopyranosyl)-(3-Deoxy-3-(3-Methoxy-Benzamido)-2-O-Sulfo-B-D-Galactopyranosyl)-Sulfide; 3-deoxy-3-[(3-methoxybenzoyl)amino]-beta-D-galactopyranosyl 3-deoxy-3-[(3-methoxybenzoyl)amino]-2-O-sulfo-1-thio-beta-D-galactopyranoside
    Click to Show/Hide
External Link
CID: 73729035
TTD: D04ORP
 Compound Name Mitumomab Phase 3 [46]
Synonyms
LuVax; MelVax; BEC-2; EMD-60205; IMC-BEC2; Antimelanoma antibody, ImClone/Merck KGaA; Antimetastatic agents, ImClone/Merck KGaA; Melanoma vaccine, ImClone/Merck KGaA; GD3 ganglioside (vaccine 1), Memorial Sloan-Kettering
    Click to Show/Hide
External Link
TTD: D04FNR
 Compound Name QS-21 Phase 3 [47]
Synonyms
AC1L1U2U; C92H148O46; LS-173109; 124716-EP2295426A1
    Click to Show/Hide
External Link
CID: 60866
TTD: D03WOW
 Compound Name RemuneX Discontinued in Phase 3 [48]
External Link
TTD: D03PLR
 Compound Name 177Lu-DOTA-octreotate Phase 3 [49]
Synonyms
Lutate; Octreotate [177Lu]; Lutetium-177 octreotate; 177-Lu octreotate; 177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema; 177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrinetumor), Biosynthema; 177Lutetium DOTA0-Tyr3-Octreotate
    Click to Show/Hide
External Link
TTD: D02ZHW
 Compound Name NKTR 214 Phase 3 [50]
External Link
TTD: D02QQE
 Compound Name MAGE-A3 immunotherapeutic Phase 3 [51]
External Link
TTD: D02MPT
 Compound Name OT-101 Phase 2/3 [4]
External Link
TTD: DO5H6K
 Compound Name Imprime PGG Phase 1/2 [14]
Synonyms
Imprime PGG (TN)
    Click to Show/Hide
External Link
TTD: D0P6MW
 Compound Name NLG8189 Phase 2/3 [14]
Synonyms
1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189
    Click to Show/Hide
External Link
CID: 405012
TTD: D0B5HS
DrugBank: DB12827
 Compound Name FX005 Phase 2/3 [52]
Synonyms
TAFAMIDIS; 594839-88-0; FX-1006; 2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid; UNII-8FG9H9D31J; CHEBI:78538; 2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid; 8FG9H9D31J; 2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic Acid; C14H7Cl2NO3; 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid; Tafamidis [USAN:INN]; tafamidisum; 4his; Fx 1006; 3MI; Tafamidis (USAN/INN); SCHEMBL442508; GTPL8378; CHEMBL2103837; KS-00000TIG; DTXSID00208185; MolPort-027-352-897; BCP29089; 3096AH; ZINC43206271; BDBM50197883; AKOS017550076
    Click to Show/Hide
External Link
CID: 11001318
TTD: D04DFR
DrugBank: DB11644
 Compound Name HF10 Phase 2 [14]
Synonyms
Canerpaturev
    Click to Show/Hide
External Link
TTD: DZ4A1W
 Compound Name EDP-1503 Phase 2 [53]
External Link
TTD: DYU37E
 Compound Name mRNA-4157 Phase 2 [54]
External Link
TTD: DTY5W0
 Compound Name Tavokinogene telseplasmid Phase 2 [14]
Synonyms
TAVO
    Click to Show/Hide
External Link
TTD: DT7O8R
 Compound Name V937 Phase 2 [55]
External Link
TTD: DOYP92
 Compound Name Lifileucel Phase 2 [56]
Synonyms
LN-144
    Click to Show/Hide
External Link
TTD: DL5C1W
 Compound Name PVSRIPO Phase 2 [57]
External Link
TTD: DIWL76
 Compound Name Ad-RTS-hIL-12 Phase 2 [58]
External Link
TTD: D90UZW
 Compound Name BNT111 Phase 2 [59]
External Link
TTD: D62LIX
 Compound Name Voyager-V1 Phase 2 [60]
Synonyms
VSV-IFNBeta-NIS
    Click to Show/Hide
External Link
TTD: D4AGB6
 Compound Name GRN 1201 Phase 1 [61]
External Link
TTD: D3JN6C
 Compound Name Dorgenmeltucel-L Phase 2 [62]
External Link
TTD: D0ZO7A
 Compound Name Cancer vaccine Phase 2 [63]
Synonyms
Cancer vaccine, AVAX/Thomas Jefferson University; Vaccine (melanoma), Thomas Jefferson; Vaccine (DNP-modified), Thomas Jefferson
    Click to Show/Hide
External Link
TTD: D0Y7TC
 Compound Name GSK-2302025A Phase 2 [64]
Synonyms
PRAME ASCI (melanoma), GSK; Recombinant preferentially expressed antigen of melanoma immunotherapeutic vaccine (melanoma), GlaxoSmithKline
    Click to Show/Hide
External Link
TTD: D0X0SK
 Compound Name Interleukin-12 gene therapy Phase 2 [65]
External Link
TTD: D0U3AL
 Compound Name PF-4878691 Phase 2 [66]
Synonyms
PF-04878691; PF-4171455
    Click to Show/Hide
External Link
CID: 10309114
TTD: D0T1FC
DrugBank: DB12476
 Compound Name SentoClone Phase 2 [67]
Synonyms
Autologous T lymphocyte therapy (malignant melanoma), SentoClone; Autologous Th1 cell therapy (malignant melanoma), SentoClone
    Click to Show/Hide
External Link
TTD: D0R9FM
 Compound Name FANG vaccine Phase 3 [68]
Synonyms
FANG (TN)
    Click to Show/Hide
External Link
TTD: D0Q4NX
 Compound Name MAGE-3-transduced autologous T-cell vaccine Phase 2 [69]
Synonyms
M3TK anticancer vaccine, MolMed/Takara; MAGE-3-transduced autologous T-cell vaccine (anticancer);MAGE-3-transduced autologous T-cell vaccine (anticancer), MolMed SpA/Takara Bio
    Click to Show/Hide
External Link
TTD: D0Q0SK
 Compound Name CB-10-01 Phase 2 [70]
External Link
TTD: D0NT1S
 Compound Name APN-301 Phase 2 [71]
Synonyms
EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2
    Click to Show/Hide
External Link
TTD: D0NS7A
 Compound Name Multi-epitope tyrosinase/gp100 vaccine Phase 2 [72]
Synonyms
Melanoma vaccine, Memorial Sloan-Kettering; Multi-epitope tyrosinase/gp100 vaccine (melanoma); Multi-epitope tyrosinase/gp100 vaccine (melanoma), Memorial Sloan-Kettering
    Click to Show/Hide
External Link
TTD: D0N7FD
 Compound Name Antigen-pulsed dendritic cell vaccine Phase 2 [73]
Synonyms
Antigen-pulsed dendritic cell vaccine (melanoma)
    Click to Show/Hide
External Link
TTD: D0MI0S
 Compound Name Stage IV melanoma vaccine Phase 2 [74]
Synonyms
Stage IV melanoma vaccine, ARI; Stage IV melanoma vaccine, Adelaide Research & Innovation
    Click to Show/Hide
External Link
TTD: D0KC9U
 Compound Name MKC-1106-MT Phase 2 [75]
Synonyms
Melanoma vaccine (MART-1/tyrosinase), Mannkind
    Click to Show/Hide
External Link
TTD: D0J7MQ
 Compound Name Telomelysin Phase 2 [50]
External Link
TTD: D0I3VV
 Compound Name Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes Phase 2 [76]
Synonyms
Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma); Autologous anti-gp100 TCR gene-engineered PBLs (melanoma), NCI; Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma), National Cancer Institute
    Click to Show/Hide
External Link
TTD: D0I3VS
 Compound Name IPI-549 Phase 2 [14]
Synonyms
XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-((
    Click to Show/Hide
External Link
CID: 91933883
TTD: D0I3LO
 Compound Name Tumor infiltrating lymphocyte Phase 2 [77]
External Link
TTD: D0H8DS
 Compound Name TH-302 Phase 2 [14]
Synonyms
evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174
    Click to Show/Hide
External Link
CID: 11984561
TTD: D0H1EA
DrugBank: DB06091
 Compound Name Ontuxizumab Phase 2 [50]
Synonyms
Amatuximab
    Click to Show/Hide
External Link
TTD: D0FK9H
 Compound Name Anti-CD3 activated vaccine-primed lymphocytes Phase 2 [78]
Synonyms
VPLN tumor vaccine, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer); Monoclonal antiobody activated vaccine-primed lymphocytes (cancer), University of Michigan; Vaccine-primed lymph node (VPLN) cells, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer), University of Michigan; Anti-CD3/anti-CD28 activated vaccine-primed lymphocytes (cancer), University of Michigan
    Click to Show/Hide
External Link
TTD: D0E8KO
 Compound Name TLPLDC Phase 2 [79]
External Link
TTD: D0D0DH
 Compound Name Coxsackievirus A21 Phase 1/2 [50]
Synonyms
Cavatak (TN)
    Click to Show/Hide
External Link
TTD: D0C4BL
 Compound Name Resimmune Phase 1/2 [80]
Synonyms
A-dmDT390-bisFv immunotoxin
    Click to Show/Hide
External Link
TTD: D0C3TI
 Compound Name ABX-IL8 Phase 2 [81]
External Link
TTD: D0BF9K
 Compound Name ITIL-168 Phase 2 [82]
External Link
TTD: D0B6AZ
 Compound Name Hi-8 PrimeBoost therapeutic melanoma vaccine Phase 2 [83]
Synonyms
Hi-8 MEL; Melanoma therapeutic vaccine, Oxxon; PSG2.Mel3; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxford BioMedica; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Lead Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Pharmaccine therapy (melanoma), Oxxon; DNA/MVA immunotherapy (melanoma), Oxxon; MEL-1 immunotherapy (melanoma), Oxxon; Melanoma immunotherapy (Prime-Boost), Oxxon
    Click to Show/Hide
External Link
TTD: D0A9BI
 Compound Name GRN-1201 Phase 1 [50]
External Link
TTD: D0A3CH
 Compound Name CYT-004-MelQbG10 Phase 2 [84]
Synonyms
Immunodrug vaccine (melanoma), Cytos; QbG10 Immunodrug carrier (cancer), Cytos
    Click to Show/Hide
External Link
TTD: D08KAD
 Compound Name GSK3377794 Phase 2 [14]
External Link
TTD: D08FWJ
 Compound Name Gp100:209-217(210M) peptide vaccine Phase 2 [85]
Synonyms
Gp100 melanoma-associated antigen vaccine, NCI; Gp100:209-217(210M) peptide vaccine (melanoma); Gp100:209-217(210M) peptide vaccine (melanoma), NCI
    Click to Show/Hide
External Link
TTD: D08DWM
 Compound Name LN-144 Phase 2 [50]
External Link
TTD: D08DIU
 Compound Name MLN2480 Phase 2 [86]
Synonyms
VWMJHAFYPMOMGF-ZCFIWIBFSA-N; 1096708-71-2; MLN 2480; BIIB-024; Tak-580; MLN-2480; BIIB024; UNII-ZN90E4027M; BIIB 024; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-; ZN90E4027M; (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-; AMG 2112819
    Click to Show/Hide
External Link
CID: 25161177
TTD: D07IEU
DrugBank: DB15266
 Compound Name ARC-100 Phase 2 [87]
Synonyms
SCHEMBL13011610
    Click to Show/Hide
External Link
CID: 57339443
TTD: D07GCK
 Compound Name AG140699 Phase 2 [88]
External Link
TTD: D06KZL
 Compound Name E7016 Phase 2 [89]
Synonyms
UNII-M8926C7ILX; E-7016; M8926C7ILX; 902128-92-1; SCHEMBL1319757; CHEMBL3527000; BDBM97563; GPI 21016; GPI-21016; SB16889; Benzopyrano(4,3,2-de)phthalazin-3(2H)-one, 10-((4-hydroxy-1-piperidinyl)methyl)-; US8470825, 4i; E 7016
    Click to Show/Hide
External Link
CID: 11660296
TTD: D06DHB
 Compound Name GR-MD-02 Phase 2 [90]
Synonyms
Belapectin
    Click to Show/Hide
External Link
TTD: D06BKH
 Compound Name PLX8394 Phase 2 [91]
External Link
CID: 90116675
TTD: D05HTS
 Compound Name Hi8 melanoma vaccine Phase 2 [92]
External Link
TTD: D04HMK
 Compound Name GCAN 101 Phase 2 [93]
External Link
TTD: D03TNG
 Compound Name MSB0010445 Phase 2 [94]
External Link
TTD: D03LAI
 Compound Name RAF265 Phase 2 [95]
Synonyms
927880-90-8; CHIR-265; RAF 265; RAF-265; CHIR 265; RAF265 (CHIR-265); 1-Methyl-5-[[2-[5-(trifluoromethyl)-1h-imidazol-2-yl]-4-pyridinyl]oxy]-n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine; CHIR265; RAF265(CHIR-265); UNII-8O434L3768; 8O434L3768; 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine; 1-Methyl-5-({2-[5-(Trifluoromethyl)-1h-Imidazol-2-Yl]pyridin-4-Yl}oxy)-N-[4-(Trifluoromethyl)phenyl]-1h-Benzimidazol-2-Amine; PubChem22594
    Click to Show/Hide
External Link
CID: 11656518
TTD: D03AND
DrugBank: DB05984
 Compound Name Urelumab Phase 2 [96]
External Link
TTD: D02ZMB
 Compound Name MORAb-004 Phase 2 [97]
External Link
TTD: D02RKG
 Compound Name APX005M Phase 2 [98]
External Link
TTD: D01ZLK
 Compound Name Leuvectin Phase 2 [99]
Synonyms
IL-2 gene therapy, Vical; Cytofectin (IL-2), Vical; Gene therapy (interleukin-2), Vical
    Click to Show/Hide
External Link
TTD: D01WHC
 Compound Name BVD-523 Phase 2 [100]
External Link
CID: 11719003
TTD: D01IED
DrugBank: DB13930
 Compound Name MGCD-0103 Phase 2 [4]
Synonyms
Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
    Click to Show/Hide
External Link
CID: 9865515
TTD: D00FHR
DrugBank: DB11830
 Compound Name Polynoma-1 Phase 2 [101]
Synonyms
Polyvalent melanoma vaccine, Vaccinoma
    Click to Show/Hide
External Link
TTD: D00DSV
 Compound Name ENB003 Phase 1/2 [102]
Synonyms
2364572-10-9; AAY8R26VDX; BQ 788-d2; BQ-788, di(methyl-d)-; CHEMBL5095234; D-Norleucine, N-((cis-2,6-di(methyl-d)-1-piperidinyl)carbonyl)-4-methyl-L-leucyl-1-(methoxycarbonyl)-D-tryptophyl-, sodium salt; Enb 003; ENB 003 [WHO-DD]; ENB003; ENB-003; UNII-AAY8R26VDX; Vodudeutentan sodium
    Click to Show/Hide
External Link
CID: 145722637
TTD: DUOX13
 Compound Name HL-085 Phase 1/2 [103]
External Link
TTD: DJ8TN2
 Compound Name NKTR-262 Phase 1/2 [4]
External Link
TTD: D8JN5H
 Compound Name Delolimogene mupadenorepvec Phase 1/2 [104]
Synonyms
LOAd703
    Click to Show/Hide
External Link
TTD: D5V7XP
 Compound Name Antigen-specific melanoma vaccine Phase 1/2 [105]
External Link
TTD: D0Z2UY
 Compound Name ImmuFact IMP321 Phase 1/2 [106]
External Link
TTD: D0U5AN
 Compound Name NY-ESO-TCR Phase 1/2 [50]
External Link
TTD: D0TN1N
 Compound Name LXS196 Phase 1/2 [14]
Synonyms
XXJXHXJWQSCNPX-UHFFFAOYSA-N; 1874276-76-2; LXS-196; NVP-LXS196; SCHEMBL17506262; CHEMBL3982723; LXS 196; BDBM251460; EX-A2690; BCP20781; ZINC584641445; CS-7529; HY-101569; US9452998, 9; 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide
    Click to Show/Hide
External Link
CID: 118873253
TTD: D0R7HL
 Compound Name AU-011 Phase 1/2 [14]
External Link
TTD: D0R0NX
 Compound Name MAGE-A10 TCR Phase 1/2 [4]
External Link
TTD: D0L1CO
 Compound Name TRX-518 Phase 1/2 [107]
Synonyms
GITR monoclonal antibody (cancer/viral infection), TolerRx; Glucocorticoid-induced TNF receptor monoclonal antibody (viral infection/cancer), TolerRx; GITR mAb (IgG/iv, cancer/viral infection), TolerRx
    Click to Show/Hide
External Link
TTD: D0J1MO
 Compound Name IMCnyeso Phase 1/2 [4]
External Link
TTD: D0I9YM
 Compound Name LAG525 Phase 1/2 [14]
External Link
TTD: D0E4LS
 Compound Name NCI-4650 Phase 1/2 [4]
External Link
TTD: D07YNC
 Compound Name Ad-IL-12 DNA therapeutic Phase 1/2 [108]
Synonyms
INXN-2001
    Click to Show/Hide
External Link
TTD: D06LUI
 Compound Name SCIB-1 Phase 1/2 [109]
Synonyms
SCIB-5; SCIB-1 DNA vaccine (melanoma, TriGrid), Scancell; Anti-TRP-2/ anti-gp100 monoclonal antibody vaccine (melanoma), Scancell
    Click to Show/Hide
External Link
TTD: D06AWA
 Compound Name ImmunoVEX-timelan Phase 1/2 [110]
External Link
TTD: D01EYR
 Compound Name CLL442 Phase 1/2 [14]
External Link
TTD: D01DIM
 Compound Name ONCOS-102 Phase 1/2 [50]
Synonyms
CGTG-102
    Click to Show/Hide
External Link
TTD: D00NBW
 Compound Name AV-MEL-1 Phase 1 [111]
External Link
TTD: DX06ZU
 Compound Name CV8102 Phase 1 [112]
External Link
TTD: DVU2H8
 Compound Name GEN-011 Phase 1 [113]
External Link
TTD: DR1YQ7
 Compound Name INXN 2001 Phase 1 [114]
External Link
TTD: DMP6A9
 Compound Name ADP-A2M10 Phase 1 [115]
External Link
TTD: DM38KC
 Compound Name CDX-1140 Phase 1 [116]
External Link
TTD: DKM7S3
 Compound Name PF-07284890 Phase 1 [117]
Synonyms
1-Propanesulfonamide, N-(2-chloro-3-((3,4-dihydro-3,5-dimethyl-4-oxo-6-quinazolinyl)amino)-4-fluorophenyl)-3-fluoro-; 2573781-75-4; AR00504461; ARRY461; ARRY-461; ARRY-461; BDBM565133; CHEMBL5095256; CS-0564141; EX-A7593; GTPL12096; HY-147405; JNJ5N2RH5W; N-(2-chloro-3-((3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide; PF07284890; PF-07284890; PF-07284890; SCHEMBL22831935; Tinlorafenib; tinlorafenib [INN]; Tinlorafenib [USAN]; UNII-JNJ5N2RH5W; US11414404, Ex. # 10; WHO 12353
    Click to Show/Hide
External Link
CID: 155434855
TTD: DJ8QW7
 Compound Name XmAb20717 Phase 1 [118]
Synonyms
XmAb717
    Click to Show/Hide
External Link
TTD: DD1TJ8
 Compound Name SX-682 Phase 1 [119]
Synonyms
1648843-04-2; UNII-H5212R2DPM; H5212R2DPM; SX682; (2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; CHEMBL4297480; GTPL10165; BCP32154; EX-A4295; MFCD28502254; s8947; SX 682; SB17394; HY-119339; CS-0067128; [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid; 2-(2-Dihydroxyboryl-5-trifluoromethoxybenzylsulfanyl)pyrimidine-5-carboxylic acid (4-fluorophenyl)amide; B-(2-(((5-(((4-Fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; Boronic acid, B-(2-(((5-(((4-fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)-
    Click to Show/Hide
External Link
CID: 90467234
TTD: DAY4L1
 Compound Name SB 11285 Phase 1 [120]
External Link
TTD: DA79HM
 Compound Name CMP-001 Phase 1 [4]
Synonyms
vidutolimod
    Click to Show/Hide
External Link
TTD: D7T5AN
 Compound Name PRT1419 Phase 1 [121]
External Link
TTD: D50CXM
 Compound Name INCAGN2385 Phase 1 [122]
External Link
TTD: D4KTA9
 Compound Name TBX-3400 Phase 1 [123]
External Link
TTD: D2DB5T
 Compound Name Ifx-Hu2.0 Phase 1 [124]
External Link
TTD: D1NC2O
 Compound Name VCL-1M01 Phase 1 [125]
Synonyms
VCL-IM01; EPT (plasmid DNA), Vical; IL-2/EP; MedPulser, cancer (plasmid DNA), Vical; Plasmid DNA (transdermal, EPT), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma); IL-2 gene therapy (pVCL-1102 plasmid DNA vector, melanoma), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma), Vical
    Click to Show/Hide
External Link
TTD: D0ZM5E
 Compound Name GPA-TriMAR-T cells Phase 1 [126]
External Link
TTD: D0YU0L
 Compound Name PTI-188 Phase 1 [127]
External Link
TTD: D0Y7SN
 Compound Name Dendritic cancer cell vaccine Phase 1 [128]
External Link
TTD: D0Y0RF
 Compound Name BETULINIC ACID Phase 1 [129]
Synonyms
472-15-1; Mairin; Betulic acid; NSC 113090; CCRIS 6748; 3-Hydroxylup-20(29)-en-28-oic acid; UNII-4G6A18707N; 3beta-Hydroxy-20(29)-lupaene-28-oic acid; EINECS 207-448-8; NSC677578; als-357; NSC 677578; CHEMBL269277; CHEBI:3087; 3beta-Hydroxy-lup-20(29)-en-28-oic acid; 4G6A18707N; Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3beta)-; AK-72848; Lupatic Acid; SMR000445624
    Click to Show/Hide
External Link
CID: 64971
TTD: D0R9YR
DrugBank: DB12480
 Compound Name Multipeptide vaccine combination Phase 1 [130]
Synonyms
Multipeptide vaccine combination (melanoma); Multipeptide vaccine combination (melanoma), Ludwig; MAGE-10.A2+ Melan-A ELA + NY-ESO-1b + tyrosinase + GM-CSF multipeptide vaccine (melanoma), Ludwig; MAGE-10.A2 + Melan-A ELA + NY-ESO-1b + tyrosinase + GM-CSF multipeptide vaccine (melanoma), Ludwig/Columbia
    Click to Show/Hide
External Link
TTD: D0R2LY
 Compound Name NEO-PV-01 Phase 1 [4]
External Link
TTD: D0Q6AU
 Compound Name Adoptive T-cell therapy Phase 1 [131]
Synonyms
Adoptive T-cell therapy (cancer)
    Click to Show/Hide
External Link
TTD: D0P4JJ
 Compound Name Vaccimel Phase 1 [132]
Synonyms
Melanoma cell line vaccine (cancer), Centro de Investigaciones Oncologicas; Autologous dendritic cells + allogeneic melanoma cell lines vaccine, Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires; Dendritic cells + apoptotic/necrotic allogeneic melanoma cell lines vaccine, Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires; DC/Apo-Nec vaccine (melanoma), Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires
    Click to Show/Hide
External Link
TTD: D0LT2Z
 Compound Name Lipovaxin-MM Phase 1 [133]
Synonyms
Dendritic cell-specific antigen targeting vaccine (liposome/nanoparticle/intravenous, melanoma), Lipotek
    Click to Show/Hide
External Link
TTD: D0L2OT
 Compound Name GSK-2241658A Phase 1 [134]
Synonyms
NY-ESO-1 ASCI (melanoma), GSK; Recombinant NY-ESO-1 antigen immunotherapeutic vaccine (melanoma), GlaxoSmithKline; 2241658A
    Click to Show/Hide
External Link
TTD: D0IA5O
 Compound Name ICON-1 Phase 1 [50]
External Link
TTD: D0H6UL
 Compound Name PLX-4720 Phase 1 [135]
Synonyms
PLX 4720; PLX4720 (BRAF inhibitor)
    Click to Show/Hide
External Link
CID: 24180719
TTD: D0F5JZ
DrugBank: DB06999
 Compound Name AE-08 Phase 1 [136]
External Link
TTD: D0F5GF
 Compound Name TAK-202 Phase 1 [50]
External Link
TTD: D0DT2S
 Compound Name Autologous T Cells Expressing MET scFv CAR Phase 1 [137]
External Link
TTD: D0D1HI
 Compound Name AEB701 Phase 1 [138]
External Link
TTD: D0B2NF
 Compound Name UV1 + GM-CSF vaccine Phase 1 [4]
External Link
TTD: D09UMR
 Compound Name AMEP Phase 1 [139]
Synonyms
(Aminomethyl)phosphonic acid; 1066-51-9; AMINOMETHYLPHOSPHONIC ACID; Aminomethanephosphonic acid; 1-Aminomethylphosphonic acid; 1-Aminomethylphosphonate; Amino methane phosphoric acid; Caswell No. 037C; Phosphaglycine; (1-Aminomethyl)phosphonic acid; Phosphonic acid, aminomethyl-; UNII-90825O5C1U; Phosphonic acid, (aminomethyl)-; Aminomethylphosphonic acid (AMPA); NSC 30076; EPA Pesticide Chemical Code 207800; CHEBI:28812; MGRVRXRGTBOSHW-UHFFFAOYSA-N; (Aminomethyl)phosphonic acid, 99%; MFCD00008105; GEO-00169; 90825O5C1U
    Click to Show/Hide
External Link
CID: 14017
TTD: D08XBF
 Compound Name Melanoma DNA vaccine Phase 1 [140]
External Link
TTD: D07YZQ
 Compound Name DEDN-6526A Phase 1 [141]
External Link
TTD: D07XXT
 Compound Name IL-2 pDNA Phase 1 [142]
External Link
TTD: D07JSX
 Compound Name AT13387 Phase 1 [143]
Synonyms
AT-13387
    Click to Show/Hide
External Link
CID: 11955716
TTD: D06YSP
DrugBank: DB06306
 Compound Name Ioflubenzamide (131I) Phase 1 [144]
Synonyms
Solazed; Ioflubenzamide I-131; MIP-1104; MIP-1143; MIP-1144; MIP-1145; ZK-BA; Iodine-123-Solazed; Iodine-131-Solazed; MIP-1145-[123I]; MIP-1145-[131I]; Radiolabeled benzamides (melanoma), Bayer; Radiolabeled benzamides (melanoma), Molecular Insight; Iodine-123-ZK-BA; Iodine-131-ZK-BA; Melanin-targeting radiodiagnostic (melanoma), Bayer/Molecular Insight; Melanin-targeting radiotherapeutic (melanoma), Bayer/Molecular Insight; 123I-MIP-1145; 123I-Solazed; 123I-ZK-BA
    Click to Show/Hide
External Link
CID: 24828760
TTD: D06SYN
 Compound Name SAM-6 Phase 1 [145]
External Link
TTD: D06PZC
 Compound Name Flanvotumab Phase 1 [146]
Synonyms
IMC-20D7S; Gp75 monoclonal antibodies (melanoma), ImClone; Gp75 mAb (melanoma), ImClone/Eli Lilly; GP75/TRP1 mAbs (melanoma), ImClone/Eli Lilly
    Click to Show/Hide
External Link
TTD: D05WQT
 Compound Name CAR-T cells recognizing EpCAM Phase 1 [147]
External Link
TTD: D04RNG
 Compound Name DC-IL-12 DNA therapeutic Phase 1 [148]
Synonyms
INXN-3001
    Click to Show/Hide
External Link
TTD: D03OKS
 Compound Name LV305 Phase 1 [149]
Synonyms
NY-ESO-1 Zvex
    Click to Show/Hide
External Link
TTD: D02XTT
 Compound Name TTI-621 Phase 1 [4]
External Link
TTD: D01CUO
 Compound Name PRAME antigen-specific cancer immunotherapeutic Phase 1 [150]
External Link
TTD: D00AHT
 Compound Name Nuleusin Discontinued in Phase 3 [151]
Synonyms
IL-2 (subcutaneous formulation, RCC/MM), 3SBio
    Click to Show/Hide
External Link
TTD: D0PE0D
 Compound Name IDD-3 Discontinued in Phase 2 [152]
Synonyms
Uvidem; Dendritophage + melanoma tumor cell lysate; Melanoma vaccine, Immuno-Designed Molecules/ IDM Pharma; Vaccine (melanoma), Immuno-Designed Molecules /IDM Pharma
    Click to Show/Hide
External Link
TTD: D0PH0M
 Compound Name AN-9 Discontinued in Phase 2 [153]
Synonyms
Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE
    Click to Show/Hide
External Link
CID: 60748
TTD: D0MP2U
DrugBank: DB05103
 Compound Name BIWB-1 Discontinued in Phase 2 [154]
Synonyms
Melanoma vaccine (autologous), Boehringer Ingelheim/Bender; IL-2 gene therapy (autologous), Boehringer Ingelheim/Bender
    Click to Show/Hide
External Link
TTD: D0C7OQ
 Compound Name Melanoma vaccine (ALVAC) Discontinued in Phase 2 [155]
Synonyms
Melanoma vaccine (ALVAC), sanofi pasteur; Melanoma vaccine (gp100/MAGE-1/MAGE-3/MART-1/NY-ESO-1, ALVAC), sanofi pasteur
    Click to Show/Hide
External Link
TTD: D0C1EO
 Compound Name TriGem Discontinued in Phase 2 [156]
Synonyms
Monoclonal antibody 1A7, Titan Pharmaceuticals; Anti-I17 antibody, Trilex
    Click to Show/Hide
External Link
TTD: D08GEX
 Compound Name Melaxin Discontinued in Phase 2 [157]
Synonyms
Autologous dendritoma vaccine (sc, melanoma), Oncolix
    Click to Show/Hide
External Link
TTD: D07FDV
 Compound Name Ecromeximab Discontinued in Phase 2 [158]
External Link
TTD: D05PWZ
 Compound Name XomaZyme-Mel Discontinued in Phase 2 [159]
Synonyms
XMMME-0001-RTA
    Click to Show/Hide
External Link
TTD: D03WSE
 Compound Name Zeniplatin Discontinued in Phase 2 [160]
Synonyms
CL-286558
    Click to Show/Hide
External Link
CID: 56840898
TTD: D00CFB
 Compound Name ODC-0501 Discontinued in Phase 1/2 [161]
Synonyms
Dendritic cell vaccine (melanoma), ODC; Vaccine (melanoma), ODC
    Click to Show/Hide
External Link
TTD: D02FEJ
 Compound Name RG-7256 Discontinued in Phase 1 [162]
Synonyms
B-raf inhibitor (melanoma), Roche/Plexxikon
    Click to Show/Hide
External Link
TTD: D0RV7J
 Compound Name RG7636 Discontinued in Phase 1 [163]
External Link
TTD: D0J0IJ
 Compound Name ABX-MA1 Discontinued in Phase 1 [164]
Synonyms
Anti-MUC18 MAb, Abgenix
    Click to Show/Hide
External Link
TTD: D0G7YG
 Compound Name F-50040 Discontinued in Phase 1 [165]
Synonyms
Metastatic melanoma vaccine, Pierre Fabre; P40-ELA; Metastatic melanoma vaccine, BioMerieux-Pierre Fabre; Vaccine (melanoma), Pierre Fabre; Vaccine (melanoma), BioMerieux-Pierre Fabre
    Click to Show/Hide
External Link
TTD: D07CQJ
 Compound Name ANAVEX 1007 Preclinical [166]
External Link
TTD: D0M6OW
 Compound Name DISC GM-CSF Terminated [167]
External Link
TTD: D0X4UA
 Compound Name Withaferin A Terminated [168]
Synonyms
Heat shock factor 1 inhibitor (melanoma), University of Kansas; HSF-1 inhibitor (melanoma), University of Kansas
    Click to Show/Hide
External Link
CID: 265237
TTD: D0V3PN
 Compound Name SBP-002 Terminated [169]
Synonyms
Coramsine; Solasonine + solamargine; Solasodine glycosides (cancer, injectable formulation), Solbec; Solasodine glycosides (psoriasis, cream formulation), Solbec; Solasonine + solamargine (cancer), Solbec; Solasonine + solamargine (psoriasis), Solbec; SBP-002 (intravenous, cancer), Solbec; SBP-002 (psoriasis, cream formulation), Solbec
    Click to Show/Hide
External Link
TTD: D0G0UZ
 Compound Name RAAV vaccine Terminated [170]
External Link
TTD: D0C3DH
 Compound Name Novovac-M1 Terminated [171]
External Link
TTD: D01CJB
 Compound Name VLD-631 Investigative [172]
External Link
TTD: D0ZE7B
 Compound Name SMT-C2100 Investigative [172]
External Link
TTD: D0Z4YK
 Compound Name TOCA-621 Investigative [172]
Synonyms
Viral vector-delivered interferon gamma gene therapy (malignant melanoma), Tocagen
    Click to Show/Hide
External Link
TTD: D0Z3ZF
 Compound Name NVX-412 Investigative [172]
External Link
TTD: D0XU4O
 Compound Name G3139 + Dacarbazine Investigative [173]
External Link
CID: 91865905
TTD: D0XU1I
 Compound Name VitiGam Investigative [172]
External Link
TTD: D0X8EE
 Compound Name CGEN-791 Investigative [172]
External Link
TTD: D0X4AN
 Compound Name IMX-MEL1 Investigative [172]
Synonyms
Melanoma therapeutic vaccine, Imaxio
    Click to Show/Hide
External Link
TTD: D0T6PF
 Compound Name Lm Melanoma Investigative [172]
Synonyms
Recombinant bacterial vector vaccine (melanoma), Aduro BioTech/New York University
    Click to Show/Hide
External Link
TTD: D0R2YD
 Compound Name ADS-NPTMZ-1 Investigative [172]
External Link
TTD: D0P6CQ
 Compound Name Narciclasine Investigative [174]
Synonyms
Lycoricidinol; 29477-83-6; Lycoricidin-A; Narciclasina; NSC 266535; BRN 1087400; NSC266535; Lycorcidinol; Nacriclasine; C14H13NO7; CHEMBL98745; 3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2H)-one; CHEBI:70169; (2s,3r,4s,4ar)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2h)-one; (2S,3R,4S,4aR)-2,3,4,7-Tetrahydroxy-3,4,4a,5-tetrahydro-2H-[1,3]dioxolo[4,5-j]phenanthridin-6-one
    Click to Show/Hide
External Link
CID: 72376
TTD: D0OQ1I
 Compound Name 111In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide (melanoma), NuView/University of New Mexico Investigative [172]
Synonyms
Imaging agent (melanoma), NuView; 111In-DOTA-GlyGlu-CycMSH (melanoma), NuView/University of New Mexico
    Click to Show/Hide
External Link
TTD: D0N7XY
 Compound Name Ektomun Investigative [172]
Synonyms
Antibody (melanoma), Trion
    Click to Show/Hide
External Link
TTD: D0L8TP
 Compound Name PDS-0102 Investigative [172]
Synonyms
Versamune-Melanoma; Vaccine (cationic lipid nanoparticle formulation, melanoma), PDS Biotechnology
    Click to Show/Hide
External Link
TTD: D0H7OO
 Compound Name MTI-SAM3 Investigative [172]
External Link
TTD: D0E7IZ
 Compound Name Box-5 Investigative [172]
Synonyms
Wnt-5a antagonist (peptide, melanoma/metastasis), WntResearch
    Click to Show/Hide
External Link
TTD: D0E0DS
 Compound Name 20D75 Investigative [172]
External Link
TTD: D0D3LZ
 Compound Name BCL-005 Investigative [172]
External Link
TTD: D0C6XD
 Compound Name 3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile Investigative [175]
External Link
TTD: D0A3SQ
 Compound Name MT-062 Investigative [176]
Synonyms
EGFR inhibitor (melanoma), Medisyn Technologies
    Click to Show/Hide
External Link
TTD: D08RXW
 Compound Name 1,3-bis(1,3-benzothiazol-2-ylthio)acetone Investigative [175]
Synonyms
1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propan-2-one; MLS000533100; AC1LOHTK; CBMicro_026328; CHEMBL1526448; MolPort-002-158-967; HMS2496A11; ZINC1029672; 1,3-dibenzothiazol-2-ylthioacetone; STK733322; AKOS001750462; MCULE-2850305009; ST006263; SMR000140538; BIM-0026345.P001; 1,3-bis(benzo[d]thiazol-2-ylthio)propan-2-one; SR-01000535355; SR-01000535355-1; 1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propane-2-one; F1563-0006; A2660/0113409
    Click to Show/Hide
External Link
CID: 1240423
TTD: D07DZS
 Compound Name PRAME-SLP Investigative [172]
Synonyms
Peptide vaccine(cancer), ISA Pharmaceuticals; Preferentially expressed antigen based vaccine (SLP technology/peptide, melanoma), ISA
    Click to Show/Hide
External Link
TTD: D06RYG
 Compound Name AEZS-120 Investigative [172]
Synonyms
Cancer vaccine (bacterial vector), University of Wurzburg/AEterna Zentaris
    Click to Show/Hide
External Link
TTD: D06KGC
 Compound Name 5-fluoro-1H-indole-2-carboxylic acid Investigative [175]
Synonyms
5-Fluoroindole-2-carboxylic acid; 399-76-8; 2-Carboxy-5-fluoroindole; 1H-Indole-2-carboxylic acid, 5-fluoro-; CHEMBL23507; MLS000080089; WTXBRZCVLDTWLP-UHFFFAOYSA-N; MFCD00005612; SMR000037735; 5-Fluoroindole-2-carboxylic acid, 98%; Spectrum_001495; EINECS 206-919-5; PubChem1683; SpecPlus_000678; Spectrum5_001733; Opera_ID_1340; Spectrum4_001182; Spectrum3_001043; Spectrum2_001469; ACMC-209j9k; AC1Q4NE3; Lopac-265128; cid_1820; AC1Q73TI; AC1L1CB9; AC1Q73TJ; Lopac0_000071; Oprea1_012690
    Click to Show/Hide
External Link
CID: 1820
TTD: D06BFH
 Compound Name TriMixDC Investigative [177]
Synonyms
Dendritic cell vaccine (melanoma), Vrije Universiteit Brussel; TriMixDC (melanoma, intrademal), Universite Libre de Bruxelles
    Click to Show/Hide
External Link
TTD: D04PFD
 Compound Name OP-03 Investigative [172]
Synonyms
OP-03 program (prodrug, melanoma); OP-03 program (prodrug, melanoma), Onco-Pharmakon
    Click to Show/Hide
External Link
TTD: D04EFB
 Compound Name LG-723 Investigative [172]
External Link
TTD: D01VZQ
 Compound Name LY-1-100 Investigative [172]
Synonyms
SMART derivatives (melanoma); LY-2-45; SMART derivatives (melanoma), University of Tennessee
    Click to Show/Hide
External Link
TTD: D01NKF
 Compound Name Lovaxin M Investigative [172]
Synonyms
HMW-MAA cancer vaccine (Listeria vector), Advaxis
    Click to Show/Hide
External Link
TTD: D00QLG
References
Ref 1 Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer Cell. 2020 Jan 13;37(1):55-70.e15. doi: 10.1016/j.ccell.2019.12.007.
Ref 2 Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
Ref 3 ClinicalTrials.gov (NCT03430297) A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma. U.S.National Institutes of Health.
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5893).
Ref 6 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075259.
Ref 7 ClinicalTrials.gov (NCT00920582) Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus. U.S. National Institutes of Health.
Ref 8 2018 FDA drug approvals. Nat Rev Drug Discov. 2019 Feb;18(2):85-89. doi: 10.1038/d41573-019-00014-x.
Ref 9 ClinicalTrials.gov (NCT03070392) Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Ref 10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7719).
Ref 13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 15 A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
Ref 16 ClinicalTrials.gov (NCT01031966) A Pilot Study to Evaluate ZADAXIN's (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine. U.S. National Institutes of Health.
Ref 17 ClinicalTrials.gov (NCT01546571) Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients. U.S. National Institutes of Health.
Ref 18 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
Ref 19 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
Ref 20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7499).
Ref 21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6888).
Ref 22 Clinical pipeline report, company report or official report of novartis.
Ref 23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8281).
Ref 24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6495).
Ref 25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7335).
Ref 26 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011670)
Ref 27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010983)
Ref 28 ClinicalTrials.gov (NCT03445533) A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) (ILLUMINATE-301). U.S. National Institutes of Health.
Ref 29 ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health.
Ref 30 ClinicalTrials.gov (NCT04830124) A Phase 2, Open Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6. U.S.National Institutes of Health.
Ref 31 ClinicalTrials.gov (NCT00050388) Phase II Trial of Allovectin-7 for Head and Neck Cancer. U.S. National Institutes of Health.
Ref 32 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7990).
Ref 33 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 34 ClinicalTrials.gov (NCT00036816) Vaccine Therapy in Treating Patients With Melanoma of the Eye. U.S. National Institutes of Health.
Ref 35 ClinicalTrials.gov (NCT01933932) Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)
Ref 36 ClinicalTrials.gov (NCT00052130) Vaccine Therapy for Patients With Stage III Melanoma. U.S. National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT02288897) PV-10 Intralesional Injection vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma. U.S. National Institutes of Health.
Ref 38 Clinical pipeline report, company report or official report of Roche.
Ref 39 ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 40 ClinicalTrials.gov (NCT02395172) Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200). U.S. National Institutes of Health.
Ref 41 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035277)
Ref 43 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8269).
Ref 44 ClinicalTrials.gov (NCT02967692) A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i). U.S. National Institutes of Health.
Ref 45 GMK (Progenics Pharmaceuticals). Curr Opin Investig Drugs. 2002 Jan;3(1):159-64.
Ref 46 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7981).
Ref 47 ClinicalTrials.gov (NCT00005052) Vaccine Therapy in Treating Patients With Primary Stage II Melanoma. U.S. National Institutes of Health.
Ref 48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019204)
Ref 49 ClinicalTrials.gov (NCT01578239) A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours. U.S. National Institutes of Health.
Ref 50 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 51 Clinical pipeline report, company report or official report of GlaxoSmithKline.
Ref 52 ClinicalTrials.gov (NCT00791492) An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy. U.S. National Institutes of Health.
Ref 53 ClinicalTrials.gov (NCT03595683) Pembrolizumab and EDP1503 in Advanced Melanoma. U.S. National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT03897881) An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942). U.S. National Institutes of Health.
Ref 55 ClinicalTrials.gov (NCT04152863) Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011). U.S. National Institutes of Health.
Ref 56 ClinicalTrials.gov (NCT02360579) Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144). U.S. National Institutes of Health.
Ref 57 ClinicalTrials.gov (NCT04577807) LUMINOS-102: PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma. U.S. National Institutes of Health.
Ref 58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033476)
Ref 59 ClinicalTrials.gov (NCT04526899) Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma. U.S.National Institutes of Health.
Ref 60 ClinicalTrials.gov (NCT04291105) Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients. U.S. National Institutes of Health.
Ref 61 ClinicalTrials.gov (NCT02696356) Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma. U.S. National Institutes of Health.
Ref 62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025020)
Ref 63 Clinical pipeline report, company report or official report of AVAX Technologies.
Ref 64 ClinicalTrials.gov (NCT01149343) Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer. U.S. National Institutes of Health.
Ref 65 Clinical pipeline report, company report or official report of OncoSec Medical.
Ref 66 ClinicalTrials.gov (NCT00189332) Use of 852A in Metastatic Cutaneous Melanoma.. U.S. National Institutes of Health.
Ref 67 ClinicalTrials.gov (NCT00991250) SentoClone Compared to Reference Treatment in Advanced Malignant Melanoma. U.S. National Institutes of Health.
Ref 68 ClinicalTrials.gov (NCT01453361) Phase II FANG in Advanced Melanoma. U.S. National Institutes of Health.
Ref 69 Clinical pipeline report, company report or official report of MolMed.
Ref 70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021032)
Ref 71 ClinicalTrials.gov (NCT00590824) Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma. U.S. National Institutes of Health.
Ref 72 ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
Ref 73 Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. Med Oncol. 2012 Dec;29(4):2966-77.
Ref 74 ClinicalTrials.gov (NCT00042783) Vaccine Therapy in Treating Patients With Stage IV Melanoma. U.S. National Institutes of Health.
Ref 75 ClinicalTrials.gov (NCT01026051) Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. U.S. National Institutes of Health.
Ref 76 ClinicalTrials.gov (NCT00509496) Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes. U.S. National Institutes of Health.
Ref 77 Clinical pipeline report, company report or official report of Lion biotechnologies.
Ref 78 Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol. 2003 Mar 1;21(5):884-90.
Ref 79 ClinicalTrials.gov (NCT02301611) Phase IIB TL + YCWP + DC in Melanoma. U.S. National Institutes of Health.
Ref 80 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038158)
Ref 81 ClinicalTrials.gov (NCT00035828) A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD. U.S. National Institutes of Health.
Ref 82 ClinicalTrials.gov (NCT05050006) A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1). U.S.National Institutes of Health.
Ref 83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013884)
Ref 84 ClinicalTrials.gov (NCT00306553) Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients. U.S. National Institutes of Health.
Ref 85 ClinicalTrials.gov (NCT00003895) Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma. U.S. National Institutes of Health.
Ref 86 ClinicalTrials.gov (NCT01425008) Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma. U.S. National Institutes of Health.
Ref 87 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019429)
Ref 88 Critical Care Nephrology, Claudio Ronco,Rinaldo Bellomo,John A. Kellum. Page(444).
Ref 89 ClinicalTrials.gov (NCT01605162) Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma. U.S. National Institutes of Health.
Ref 90 ClinicalTrials.gov (NCT02421094) Clinical Study for Non-Invasive Imaging Methods for GR-MD-02 for Treatment of Liver Fibrosis. U.S. National Institutes of Health.
Ref 91 ClinicalTrials.gov (NCT02428712) A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors. U.S. National Institutes of Health.
Ref 92 Phase I/II trial of Hi8 PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. Melanoma Research. 09/2006; 16(Supplement 1).
Ref 93 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022232)
Ref 94 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026542)
Ref 95 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5674).
Ref 96 ClinicalTrials.gov (NCT00612664) Phase II, 2nd Line Melanoma - RAND Monotherapy. U.S. National Institutes of Health.
Ref 97 ClinicalTrials.gov (NCT01574716) Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE). U.S. National Institutes of Health.
Ref 98 ClinicalTrials.gov (NCT04337931) A Study to Evaluate APX005M in Subjects With Unresectable or Metastatic Melanoma. U.S. National Institutes of Health.
Ref 99 ClinicalTrials.gov (NCT00004050) Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer. U.S. National Institutes of Health.
Ref 100 ClinicalTrials.gov (NCT03417739) A Phase II Study of BVD-523 in Metastatic Uveal Melanoma. U.S. National Institutes of Health.
Ref 101 An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
Ref 102 ClinicalTrials.gov (NCT04205227) A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
Ref 103 ClinicalTrials.gov (NCT03973151) Study of HL-085 in NRAS Mutant Advanced Melanoma. U.S. National Institutes of Health.
Ref 104 ClinicalTrials.gov (NCT04123470) A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma. U.S. National Institutes of Health.
Ref 105 A Special Report on Gene Therapy, K. K. Jain. Page(138).
Ref 106 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024121)
Ref 107 ClinicalTrials.gov (NCT01239134) Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors. U.S. National Institutes of Health.
Ref 108 Clinical pipeline report, company report or official report of ZIOPHARM.
Ref 109 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032104)
Ref 110 Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
Ref 111 ClinicalTrials.gov (NCT03743298) Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma. U.S. National Institutes of Health.
Ref 112 ClinicalTrials.gov (NCT03291002) Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC. U.S. National Institutes of Health.
Ref 113 ClinicalTrials.gov (NCT04596033) TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy. U.S. National Institutes of Health.
Ref 114 ClinicalTrials.gov (NCT01397708) Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma. U.S. National Institutes of Health.
Ref 115 Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol. 2022 Mar 18;12:818679.
Ref 116 ClinicalTrials.gov (NCT03329950) A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies. U.S. National Institutes of Health.
Ref 117 ClinicalTrials.gov (NCT04543188) A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF-07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT. U.S.National Institutes of Health.
Ref 118 ClinicalTrials.gov (NCT03517488) A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2). U.S. National Institutes of Health.
Ref 119 ClinicalTrials.gov (NCT03161431) SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab. U.S. National Institutes of Health.
Ref 120 ClinicalTrials.gov (NCT04096638) Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 121 ClinicalTrials.gov (NCT04543305) A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies. U.S. National Institutes of Health.
Ref 122 ClinicalTrials.gov (NCT04370704) Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies. U.S. National Institutes of Health.
Ref 123 ClinicalTrials.gov (NCT03385486) Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors. U.S. National Institutes of Health.
Ref 124 ClinicalTrials.gov (NCT04160065) Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC. U.S. National Institutes of Health.
Ref 125 ClinicalTrials.gov (NCT00223899) A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma. U.S. National Institutes of Health.
Ref 126 ClinicalTrials.gov (NCT03649529) Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy
Ref 127 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025308)
Ref 128 Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015 May 15;348(6236):803-8.
Ref 129 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3945).
Ref 130 Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16S (June 1 Supplement), 2005: 7551.
Ref 131 Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007 June 1; 117(6): 1466-1476.
Ref 132 A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother. 2006 Jul-Aug;29(4):444-54.
Ref 133 ClinicalTrials.gov (NCT01052142) Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma. U.S. National Institutes of Health.
Ref 134 ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health.
Ref 135 Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011;16(3):296-309.
Ref 136 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037366)
Ref 137 ClinicalTrials.gov (NCT03060356) Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
Ref 138 Nearly 800 Medicines and Vaccines in Clinical Testing For Cancer Offer New Hope to Patients. Pharmaceutical Research and Manufacturers of America report. 2014.
Ref 139 Pre-EMP-tive strike against GBM. SciBX 7(14); doi:10.1038/scibx.2014.389. April 10 2014
Ref 140 ClinicalTrials.gov (NCT00471133) Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation. U.S. National Institutes of Health.
Ref 141 ClinicalTrials.gov (NCT01522664) A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma. U.S. National Institutes of Health.
Ref 142 Phase I trial of IL-2 plasmid DNA with electroporation in metastatic melanoma, Journal of Clinical Oncology, Vol 25, No 18S (June 20 Supplement), 2007: 8578.
Ref 143 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
Ref 144 ClinicalTrials.gov (NCT00747825) Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma. U.S. National Institutes of Health.
Ref 145 ClinicalTrials.gov (NCT01727778) Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 146 ClinicalTrials.gov (NCT01137006) An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma. U.S. National Institutes of Health.
Ref 147 ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer
Ref 148 ClinicalTrials.gov (NCT00815607) Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma. U.S. National Institutes of Health.
Ref 149 ClinicalTrials.gov (NCT02122861) A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1. U.S. National Institutes of Health.
Ref 150 Clinical pipeline report, company report or official report of GlaxoSmithKline.
Ref 151 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027551)
Ref 152 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017393)
Ref 153 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004320)
Ref 154 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004906)
Ref 155 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014153)
Ref 156 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010286)
Ref 157 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028388)
Ref 158 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013219)
Ref 159 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008660)
Ref 160 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001208)
Ref 161 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021775)
Ref 162 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022593)
Ref 163 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035865)
Ref 164 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016814)
Ref 165 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016041)
Ref 166 2011 Pipeline of Anavex.
Ref 167 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008666)
Ref 168 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006527)
Ref 169 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022850)
Ref 170 Clinical pipeline report, company report or official report of MediGene AG.
Ref 171 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008898)
Ref 172 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 173 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
Ref 174 Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J. 2010 Nov;24(11):4575-84.
Ref 175 Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer. 2011 Feb 15;104(4):653-63.
Ref 176 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
Ref 177 Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383.